Skip to main content
Signal8

Profusa, Inc. (PFSA)

Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

Profusa, Inc. Common Stock logo

Profusa, Inc. Common Stock

NASDAQ:PFSAHealthcare
AH+0.00%$0.6171
Close$0.6171-0.21%
Mkt Cap$374K
Float465K
O/S606K
VOL215K sh
$ Vol$136K
RVOL0.09×
Inst Own0.7%
SI16.8%
Dilution
Profusa, Inc. Common Stock logoNASDAQ:PFSAAH$0.6171+0.00%
Pipeline1 lead-sponsored trial·1 active0 completed

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
  • Not applicable
    Active, not recruiting

    Monitoring Local Tissue Oxygen Changes Using the Wireless Lumee Oxygen Platform in Correlation to TcPO2

    Wireless Lumee Oxygen Platform

    Peripheral Artery Disease

    Enrollment
    53
    Start
    Dec 2020
    Primary Completion
    Mar 2027est.
    Completion
    Mar 2028est.
    NCT04514861
Search ClinicalTrials.gov for “Profusa”